Reuters
24 Dec 2025, 20:24 UTC · 43w ago
Biohaven's depression drug fails mid-stage trial, shares fall
Impact · against what's priced in
Biohaven's stock faces downward pressure following the failure of a mid-stage trial for its experimental depression drug. This event, coupled with a series of recent regulatory setbacks, significantly impairs the value of its pipeline and diminishes growth expectations.
- BHVN−0.80
No priced-in read yet
- In context
The failure of a mid-stage trial for a key depression drug asset removes a significant path to future revenue and suggests a pattern of pipeline instability.
Read from the article alone
Top 1 mover · tap to explore
